Biomarkers for REM sleep behavior disorder in idiopathic and narcoleptic patients by Antelmi, Elena et al.
BRIEF COMMUNICATION
Biomarkers for REM sleep behavior disorder in idiopathic
and narcoleptic patients
Elena Antelmi1,2 , Fabio Pizza1,2, Vincenzo Donadio1,2, Marco Filardi1, Yuri L. Sosero1,
Alex Incensi2, Stefano Vandi1,2, Monica Moresco1,2, Raffaele Ferri3, Sara Marelli4,5,
Luigi Ferini-Strambi4,5, Rocco Liguori1,2 & Giuseppe Plazzi1,2
1Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum, University of Bologna, Bologna, Italy
2IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
3Sleep Research Centre, Oasi Research Institute - IRCCS, Troina, Italy
4“Vita-Salute” San Raffaele University, Milan, Italy
5Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Neurology - Sleep Disorders Centre, Milan, Italy
Correspondence
Giuseppe Plazzi, Department of Biomedical
and Neuromotor Sciences, University of
Bologna IRCCS Istituto delle Scienze
Neurologiche di Bologna, Bellaria Hospital,






Received: 20 May 2019; Accepted: 10 June
2019
Annals of Clinical and Translational
Neurology 2019; 6(9): 1872–1876
doi: 10.1002/acn3.50833
Abstract
To search for discriminating biomarkers, 30 patients with idiopathic rapid-eye-
movements sleep behavior disorder (iRBD) were compared with 17 patients
with RBD within narcolepsy type 1. Both groups underwent extensive examina-
tions, including skin biopsy searching for phosphorylated a-synuclein deposits
and whole-night video-polysomnography. Skin biopsy was positive for phos-
phorylated a-synuclein deposits in 86.7% of iRBD patients and in none of nar-
coleptic patients. The analysis of video-polysomnographic motor events showed
differences in their occurrence throughout the night in the two groups. iRBD
and RBD due to narcolepsy do have different clinical and pathological findings,
confirming a different pathophysiology.
Introduction
Rapid-eye-movements (REM) sleep behavior disorder
(RBD) is a parasomnia characterized by repeated episodes
of dream enactment associated with loss of muscle atonia
during REM sleep.1 Idiopathic (or isolated) RBD (iRBD)
has the highest positive predictive value for impending
synucleinopathies.2,3 After neurodegenerative diseases, the
second most common cause of secondary RBD is nar-
colepsy type 1 (NT1), a central hypersomnia, linked to
loss of hypocretin 1 (Hcrt-1) neurons.1
RBD is reported to occur in NT1 with a frequency
ranging between 7% and 63% and may rarely be the
heralding symptom of NT1.1,2
iRBD and RBD secondary to narcolepsy share both dis-
crete and overlapping features.1,2,4–7 While iRBD has been
consistently linked to an underlying synucleinopathy and
positive synucleinopathy at skin biopsy has been consis-
tently reported to be a biomarker of iRBD,3,8 RBD within
narcolepsy has been linked to the Hcrt-1 loss. However,
not all NT1 patients do have RBD and RBD does not
occur only in narcoleptic patients with Hcrt-1 deficiency.2
The pathophysiology of RBD within narcolepsy is there-
fore a still controversial issue.
In order to advance the understanding of these ambi-
guities and to possibly identify a discriminating marker,
we recorded clinical, neurophysiological, and pathological
biomarkers in NT1 patients with a complaint of RBD and
compared the findings with those obtained in adult
patients with iRBD.
Methods
Among 72 adult consecutive patients referred to our
clinic within the last two years (October 2016- October
2018) and receiving a final diagnosis of NT1, according
to the current criteria,1 we selected 17 patients who sub-
jectively reported a complaint of RBD, confirmed by
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video-polysomnography (vPSG).1 NT1 patients with RBD
where then compared with 30 age-matched consecutive
patients who received a final diagnosis of vPSG-confirmed
iRBD, according to the current criteria.1
Patients with alcohol-use disorder, taking antidepres-
sants, or beta-blockers or with signs of motor or cognitive
dysfunctions were excluded.
Both groups underwent extensive examinations, with
complete clinical and neurological examination. All the
motor and nonmotor symptoms were assessed by means of
history taking, except for orthostatic hypotension for which
we performed blood pressure measurement while lying-
down and after 1–3 min of standing. We also performed
neuropsychological testing, including the Brief Mental De
terioration Battery,9 brain MRI, nigrostriatal dopamine
transporter ligand [123I]ioflupane-DaTscan and skin biopsy
looking for phosphorylated a-synuclein (p-a-syn) deposits.
For skin biopsy, 3-mm punch biopsy was performed bilater-
ally, proximally (i.e., C8 paravertebral area) and distally
(10 cm above the lateral malleolus of legs). Samples were
then incubated and analyzed, as previously reported.3
In order to exclude motor symptoms, in patients with
iRBD we used the Unifying Parkinson Disease Rating
Scale Part III – UPDRS-III.
Whole-night vPSG was performed, which included
conventional electroencephalogram (at least three chan-
nels, including frontal, central, and occipital leads,
referred to the contralateral mastoid), bilateral electroocu-
logram, submentalis and anterior tibialis electromyogra-
phy, respiratory parameters, and electrocardiogram. Sleep
was scored according to standard criteria.10 Files were
exported in European Data Format and the REM Atonia
Index was computed, using the validated automatic analy-
sis implemented in Hypnolab v. 1.2 software.11
Time synchronized vPSGs were reviewed offline and
separately by two sleep experts, blinded to clinical diagno-
sis (EA and FP). All sleep stages were considered, except
for wakefulness before and after sleep onset. Movements
were scored in both NREM and REM sleep stages and
classified as elementary (if brief and nonpurposeful, as,
e.g., stereotypies, facial grimacing, pelvic movements) or
complex (if longer and purposeful, hence mimicking a
scenic behavior, likely linked to a dream mentation).12
Motor events were judged as having a stereotyped pattern
if they tended to occur with the same/similar pattern on
different occasions. The mean interscorer agreement was
0.94, with kappa values ranging from 0.85 for the label
“stereotyped pattern of simple motor activity in NREM”
to 1 for the label “presence of simple gesturing during
REM sleep.” Group differences between NT1 and iRBD in
clinical, neurophysiological, and biochemical data were
analyzed by means of chi-squared test and Mann–Whit-
ney U Test, as appropriate. False discovery rate (FDR)
was used to correct for multiple comparisons; P val-
ues < 0.05 were considered to be statistically significant.13
This study has been approved by the internal ethics
committee, and all the participants signed an informed
consent form.
Results
The final sample included 17 patients with NT1 (mean
age 64.24 years, standard deviation 12.86; 70.6 % males),
compared to 30 patients with iRBD (mean age
69.90 years, standard deviation 8.38; 83.3% males).
All patients with iRBD had a score of less than 5 at the
UDRS, Part III (mean 1.35, standard deviation 1.99).
As expected, NT1 patients had pathological values at
the Epworth Sleepiness Scale.
Patients with iRBD showed older age for RBD onset,
reported more frequently violent episodes and com-
plained more frequently of an every-night occurrence of
RBD episodes (Table 1), while all the other clinical data
were comparable between the two groups. Neurophysio-
logical data are reported in Table 1.
Motor activity/behavior during sleep
When looking at the motor activity during REM sleep, we
found that both groups had the same occurrence of simple
motor activity, which, however, in NT1 patients tended to
show more frequently an almost intra-individual stereo-
typed pattern, that is, to recur showing the same/similar
pattern whenever they occurred (although this finding did
not pass the correction for multiple comparisons). Com-
plex motor activity in NT1 patients occurred similarly in
the first and second half on the night, when compared with
iRBD patients (in whom it was mainly confined to the
second half of the night) (Table 2).
Moreover, compared to iRBD, more NT1 patients pre-
sented simple motor episodes also during NREM sleep. In
NT1 patients, simple motor episodes tended also to have
more frequently an almost intraindividual stereotyped
pattern and occurred in all NREM sleep stages, whereas
in iRBD simple motor episodes occurred mainly in lighter
sleep (Table 2). Complex motor activity during NREM,




Intraneural p-a-syn deposits at skin biopsy were found in
86.7% of iRBD patients, but in none of NT1 patients. No
differences were found for the frequency of abnormalities
at DaTscan or neuropsychological testing (Table 2).
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Discussion
Two “clear-cut” signatures were found in this study, help-
ful for the differential diagnosis between iRBD and RBD
due to NT1. First, positive skin biopsy confirmed to be
the biological fingerprint of iRBD, whereas it turned to
be always negative in NT1 patients with RBD, corroborat-
ing the hypothesis of a complete different pathophysiol-
ogy between these two conditions.
The second main finding is that while in iRBD com-
plex motor activity is confined to REM sleep, in NT1
patients with RBD, nocturnal motor activity/behaviors
recurred throughout the whole night, in both NREM and
REM sleep, and showed frequently an almost stereotyped
pattern in the same subject.
The occurrence of RBD in patients with narcolepsy has
been hypothesized to be linked to Hcrt-1 loss,9 but no
consensus has been reached for the mechanisms
involved.1,2,14 Indeed, not all patients with NT1 present
RBD and, contrary to cataplexy, RBD has not been con-
sistently associated with a deficit of Hcrt-1.2
iRBD/RBD within Parkinson disease (PD) and RBD
within NT1 share some overlapping features, from both a
clinical (i.e., hyposmia, autonomic changes, cognitive and
neuropsychiatric symptoms, sleep attacks) and a biologi-
cal (i.e., reduction of CSF-Hcrt-1 levels) stand-
point.1,2,4,15 Moreover, ictal single-photon emission
tomography studies exploring the RBD pathways in vivo
showed similar cerebral activation in patients with iRBD
and in those with RBD linked to PD or NT1.4 However,
solid evidence supports a completely different etiopatho-
genesis of the underlying diseases.2,5–7
To this regard, 86.7% of our iRBD patients, but none
of patients with NT1-RBD had positive skin biopsy for p-
a-syn deposits. This finding confirms, in this relatively
large cohort of patients, the notion that iRBD is a synu-
cleinopathy,3,8 but also corroborates the hypothesis of dif-
ferent pathophysiological processes in iRBD and NT1-
associated RBD, implying differences in the risk of con-
version to neurodegenerative disorders.
The finding of increased motor activity throughout the
whole night supports previous observations,2 and
Table 1. Comparison of clinical and neurophysiological data obtained in the two groups of patients.
iRBD (n = 30) RBD-NT1 (n = 17)
P qmean  SD or % mean  SD or %
Clinical data
Age, years 69.9  8.38 64.2  12.86 0.094
Males 83.3% 70.6% 0.305
Urinary urgency 23.3% 5.9% 0.126
Orthostatic hypotension 3.3% – 0.447
Reduction of olfaction 23.3% 5.9% 0.126
Motor symptoms 23.3% 11.8% 0.333
Cognitive symptoms 23.3% 11.8% 0.333
Psychiatric symptoms 20.0% 17.6% 0.844
Constipation 43.3% 29.40% 0.345
RBD onset, years 57.8  9.56 43.8  17.69 <0.01 <0.05
Violent RBD episodes 53.30% – <0.0005 <0.01
Everyday occurrence of RBD episodes 33.30% – <0.01 <0.05
Epworth Sleepiness Scale score 7.1  2.89 17.3  3.08 <0.0001 <0.0001
Neurophysiological data
Sleep latency, min 34.6  52.40 5.3  6.07 <0.0001 <0.0005
REM latency, min 120.0  76.34 76.5  105.20 <0.01 <0.05
Total sleep time, min 304.7  88.79 318.2  55.10 0.673
Sleep efficiency 68.9%  17.60 68.0%  12.27 0.289
N1 16.3%  9.28 11.12%  8.33 0.057
N2 46.9%  10.51 34.9%  11.34 <0.005 <0.05
N3 19.2%  8.84 29.2%  15.24 <0.05 <0.05
REM 15.7%  6.62 22.6%  9.93 <0.05 <0.05
ODI 4.9  6.49 2.9  3.52 0.335
PLMS index 24.8  28.15 24.9  21.66 0.568
Atonia index 0.53  0.21 0.63  0.21 0.153
Significant P values are in bold. min, minutes; N1-N2-N3-REM (stage 1,2,3 of NREM sleep; REM sleep); ODI, oxygen desaturation index; SD, stan-
dard deviation; PLMS, periodic limb movements during sleep; q = FDR-adjusted P-values.
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confirms a broader abnormal motor control than that
found in iRBD, where motor activity is mainly restricted
to REM sleep and occurs mostly in the second half of the
night, with a motor pattern of the episodes that is usually
more energetic-violent than that observed in RBD of NT1
patients.
In NT1 patients, elementary and complex motor activ-
ity not only recurred throughout the whole night but had
also an almost stereotyped intra-individual pattern, prob-
ably reflecting the typical instability of sleep, with subcon-
tinuous sleep-transitionns16,17 and occurrence of
dissociated states1,2 that brings to a mentation reflecting
this “twilight” state.
To conclude, this study indicates that even if iRBD and
RBD-NT1 may show some similarities, they do have dif-
ferent clinical and pathological findings.
Both vPSG and skin biopsy can discriminate between
these two conditions.
A notable finding is the much greater rate of positive
synuclein skin biopsy (86.7%) compared to the rate of
abnormal DaTscan (36.7%) in the 30 iRBD patients,
indicating a much greater sensitivity of the former test if
used as a biomarker in patients with iRBD.
This study confirms that skin biopsy confirms is a fea-
sible, reliable, specific, and sensitive marker of the under-
lying synucleinopathy in iRBD patients.
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Table 2. Comparison of data on motor episodes during REM sleep and markers of degeneration obtained in the two groups of patients.
iRBD (n = 30) RBD-NT1 (n = 17)
P qMean  SD or % Mean  SD or %
Motor episodes in REM sleep
Presence of simple motor episodes 93.1% 94.1% 0.893
Number of simple episodes 9.3  7.35 12.4  12.65 0.659
Intraindividual stereotypy of events 40.7% 75% <0.05
Presence of complex motor episodes 58.6% 70.6% 0.417
Number of complex episodes 5.2  3.91 5.6  4.98 0.929
Mean duration of complex episodes, seconds 20.7  16.30 15.1  18.91 0.071
Intraindividual stereotypy of events 37.5% 66.7% 0.127
Violent/energetic pattern 27.6% 5.9% 0.073
Episodes occurring in the 2nd half of the night 93.8% 42.3% <0.05 <0.05
Episodes occurring in the 1st and 2nd half of the night 6.2% 57.7%
Motor episodes in NREM sleep
Simple motor episodes 44.8% 76.5% <0.05
Number of episodes 6.8  6.40 21.5  15.52 <0.005 <0.05
Intraindividual stereotypy of events 33.3% 76.9% <0.05
Distribution of motor episodes




Presence of complex motor episodes 0 15% 0.054
Markers of neurodegeneration
Pathological DaTscan§ 36.7% 13.3% 0.104
Pathological neuropsychological tests 3.3% 0 0.475
Single deficits at neuropsychological tests 50% 20% 0.053
Positive skin biopsy for p-a-syn 86.7% 0 <0.0001 <0.0001
N1, N2, N3, stage 1, 2 and 3 of NREM sleep; EF, executive function; VF, verbal fluency; VL, verbal logic; VM, verbal memory; VSA, visuo-spatial abili-
ties, p-a-syn, phosphorylated alpha synuclein; q, FDR-adjusted P-values. Significant P values are in bold. § = 2 NT1 patients = putamen one-side; 11
iRBD patients = # 5 putamen one-side; # 1 caudate one side; # 1 putamen and caudate = # 3 = putamen bilaterally; # 1 caudate bilaterally.
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